Anti-VEGF Therapy and the Retina: An Update. (31st August 2015)

• Record Type: Journal Article
• Authors: Tah, Vikas; Orlans, Harry O.; Hyer, Jonathan; Casswell, Edward; Din, Nizar; Sri Shanmuganathan, Vishnu; Ramskold, Louise; Pasu, Saruban
• Other Names: Macky Tamer A. Academic Editor.
• Is Part Of: Journal of ophthalmology. Volume 2015(2015)
• Publication Date: 2015-08-31
• Subjects: Ophthalmology -- Periodicals; Eye Diseases; Ophthalmology; Ophthalmology; Electronic journals; Periodicals; Periodicals; Fulltext; Internet Resources; Periodicals; 617.7
• DOI: 10.1155/2015/627674
• Languages: English
• ISSNs: 2090-004X

Abstract

Abstract : Ocular angiogenesis and macular oedema are major causes of sight loss across the world. Aberrant neovascularisation, which may arise secondary to numerous disease processes, can result in reduced vision as a result of oedema, haemorrhage, and scarring. The development of antivascular endothelial growth factor (anti-VEGF) agents has revolutionised the treatment of retinal vasogenic conditions. These drugs are now commonly employed for the treatment of a plethora of ocular pathologies including choroidal neovascularisation, diabetic macular oedema, and retinal vein occlusion to name a few. In this paper, we will explore the current use of anti-VEGF in a variety of retinal diseases and the impact that these medications have had on visual outcome for patients.